News Archive

Reynolds appointed CEO of SomaLogic

SomaLogic announced today that Board of Directors member Alister W. (Al) Reynolds has agreed to become the next company Chief Executive Officer.  He is replacing Byron Hewett, who elected to step down from the role following several years of successfully leading the company through its initial growth into a successful commercial entity.

read more

Modified DNA aptamers: Two is better than one

In a study published online in the Proceedings of the National Academy of Sciences (PNAS), SomaLogic scientists report on the generation and characterization of a new class of SOMAmer that contains two different types of modified nucleotides.

read more

SomaLogic announces that it has joined the iCarbonX Digital Life Alliance

SomaLogic announced today that it has agreed to join the “Digital Life Alliance” established by iCarbonX, the China-based company founded in 2015 to build a “Global Digital Health Ecosystem that can define each person’s ‘digital life’ based on a combination of individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.”

read more

Levels of nine blood proteins can accurately predict high or low risk of serious cardiovascular events

A study published online today in the Journal of the American Medical Association (JAMA) details the first successful effort to measure at scale the levels of more than a thousand proteins in blood in patients with coronary heart disease, and describes the identification of a combination of nine specific proteins whose levels taken together can accurately predict the risk of future heart attacks, strokes, heart failure or death.

read more

Matthew (“Matt”) Norkunas, M.D., announced as new SomaLogic CFO

SomaLogic, Inc. announced today that Matthew Norkunas, M.D. has joined the company as Chief Financial Officer (CFO). Prior to SomaLogic, Dr. Norkunas was a Senior Research Analyst at Marsico Capital Management in Denver focused on biotech, pharma, life sciences, and diagnostics companies.

read more

SomaLogic completes agreement with Bristol-Myers Squibb for expanded access to SOMAmer reagents

SomaLogic, Inc. announced today that it signed an agreement with the Bristol-Myers Squibb Company (NYSE-BMY) to provide expanded access to its proprietary SOMAmer reagents. The agreement covers both the 1,310 reagents available in the current public version of the SOMAscan assay, as well as custom SOMAmer reagents developed through SomaLogic’s SOMAmer Discovery Service specifically for Bristol-Myers Squibb.

read more